We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.11 | 1.20% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 1,064,455 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/4/2024 07:15 | nobby is omnipresent. like God he resides everywhere in peoples minds | thanatos abysss | |
11/4/2024 07:14 | Every rns, product update and staff change now causes a market reaction | institutional investments | |
11/4/2024 03:52 | I can’t see Skinbiotics waiting a century for it to be available to buy somehow. Plus it might dilute and confuse their brand ? Omg | kreature | |
10/4/2024 19:15 | Maybe they will | thanatos abysss | |
10/4/2024 18:20 | Actually, Maybe not | institutional investments | |
10/4/2024 18:20 | Maybe Skinbiotics will sell it | institutional investments | |
10/4/2024 16:24 | 👻👻 | thanatos abysss | |
10/4/2024 16:20 | Sadly not by the look of it. | kreature | |
10/4/2024 16:02 | Is this our lysate product/ technology/ linked to croda launch. clr-berlin.com/produ ProRenew Complex CLR™ acts on essential features in the aging process of the skin, its ability to successfully adapt to a constantly changing environment and to effectively renew itself. ProRenew Complex CLR™ positively influences the speed and quality of epidermal growth. It has shown to effectively promote desquamation, the shedding of dead cells. ProRenew Complex CLR™ is beneficial for both the health of skin and the skin microbiota. It balances and protects the skin microbiota and supports it in dealing with day-to-day stress. ProRenew Complex CLR™ also improves the condition of the scalp and makes it less oily. It additionally leads to perceivable reduction of the sensitivity of the scalp, makes scalp tangibly healthier and reduces attributes related to dryness of the scalp. ProRenew Complex CLR™ provides important support for the skin and the scalp, even from rinse-off formulations. See how ProRenew Complex CLR™ improves epidermal growth and skin quality: | theterrier | |
10/4/2024 14:15 | Market is bemused | kreature | |
10/4/2024 14:14 | If you are looking to fully understand how the bond facility works, should be in a book called Bonds et-al for experts (Chinese version) | kreature | |
10/4/2024 14:13 | Just looking at supply and demand since the 7p rise Is the maker confused? | institutional investments | |
10/4/2024 14:11 | Bonds seem to be within et al | institutional investments | |
10/4/2024 14:09 | Is it all cash-in-hand with bond deals ? Or is it mainly et-al ? | kreature | |
10/4/2024 14:03 | Maybe the confusing part is going via a bond facility to issue a watering down to the usual crew's I looked up possible reasons for this and can't find anything viable at all in terms of value to normal investors So where is the value in it? To who | institutional investments | |
10/4/2024 13:59 | Surely bonds have to convert first in market before any transaction shows and therefore nobody bought any yet? Or, its off book and not showing at all? Very strange having looked back on past similar scenarios in more transparent markets Converting direct to II on open market is very unusual. Normally it would just be a TR1 of a conversion to market/II at X price | institutional investments | |
10/4/2024 13:57 | Not sure why a bond to II deal would show on L2 really Has me thinking ... Are you guys sure? Looks an awful like somebody else dumping to open market | institutional investments |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions